Manufacturers

Bionik, Inc.

80 Coolidge Hill Road , 02472 Watertown
USA

Telephone +1 617 926-4800
Fax +1 617 926-4808
skrebs@bioniklabs.com

This company is co-exhibitor of
Messe Düsseldorf North America

Trade fair hall

  • Hall 16 / E40-5
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 16): stand E40-5

Fairground map

MEDICA 2016 fairground map: Hall 16

Our range of products

Product categories

  • 04  Physiotherapy / Orthopaedic Technology
  • 04.12  Rehabilitation equipment and devices
  • 04  Physiotherapy / Orthopaedic Technology
  • 04.14  Training equipment

Our products

Product category: Rehabilitation equipment and devices, Training equipment

InMotion ARM with HAND Robotic Neuro Recovery System

The InMotion ARM/HAND Robotic Neurorecovery System features evidence-based, rehabilitation for patients with neurological impairements such as stroke and cerebral palsy. Our interactive technology that senses patient movements and limitations, providing assistance-as-needed in real-time. The technology not only prompts participation and provides consistency, it also encourages appropriate movement while discouraging movement that is inappropriate. By automatically and continuously adapting to and challenging each patient’s ability, the intelligent algorithms  behind InMotion robots enable clinicians to automatically deliver personalized intensive shoulder, elbow, hand and wrist sensorimotor therapy to patients with mild to severe impairments. More important, the unique therapy these systems offer promotes development of new neural pathways resulting in marked and meaningful improvement when compared with usual care and treatment. The InMotion ARM/HAND Neurorecovery System has been used by leading rehabilitation centers and universities around the world.

More Less

Product category: Rehabilitation equipment and devices, Training equipment

InMotion WRIST Robotic Neuro Recovery System

The InMotion WRIST Robotic Neurorecovery System features evidence-based, rehabilitation for patients with neurological impairment such as stroke and cerebral palsy.   Our interactive technology that senses patient movements and limitations, providing assistance-as-needed in real-time. The technology not only prompts participation and provides consistency, it also encourages appropriate movement while discouraging movement that is inappropriate. By automatically and continuously adapting to and challenging each patient’s ability, the intelligent algorithms behind InMotion robots enable clinicians to automatically deliver personalized intensive shoulder, elbow, hand and wrist sensorimotor therapy to patients with mild to severe impairments. More important, the unique therapy these systems offer promotes development of new neural pathways resulting in marked and meaningful improvement when compared with usual care and treatment.  The InMotion WRIST Neurorecovery system has been used by leading rehabilitation centers and universities around the world.

More Less

Company news

Date

Topic

Download

Nov 2, 2016

Corporate Update and Business Outlook

Bionik Laboratories Provides Corporate Update and Business Outlook

>Robotics upper and lower body development and commercial product line focused on stroke rehabilitation and mobility solutions

>Development and commercialization strategy designed to provide roboticrehabilitation product solutions from hospital to home; representing $11 billion

addressable market

>Product launch of next generation upper body commercial product line planned in Q2 2017 expected to drive revenue growth

>Compelling clinical data expected to significantly differentiate product portfolio and support marketing and reimbursement

>Robust business development strategy to identify strategic partners to expand into key markets

TORONTO and BOSTON, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Bionik Laboratories

Corp. (OTCQX:BNKL) (“Bionik” or the "Company"), a global pioneering robotics company

focused on providing rehabilitation and mobility solutions to individuals with neurological

disorders, today provided a corporate overview and business outlook including the

Company’s development and commercial strategy. The Company also summarized

anticipated events and key near-term corporate, development, clinical and regulatory

milestones.

Peter Bloch, Chief Executive Officer and Chairman of the Board, stated, “2016 has been a

transformative year for Bionik with the significant expansion of our product portfolio with

the acquisition of Interactive Motion Technologies (IMT) in April. Our product portfolio now

includes both lower and upper body robotic rehabilitation products, including three FDAcleared

commercial products and four development-stage products. Following the

completion of this transaction, the Bionik team conducted an in-depth strategic review

including a comprehensive market analysis, product pipeline development prioritization,

business development and growth focus and marketing and commercial planning. It is

clear that opportunities to unlock tremendous value for Bionik lie ahead with our focus on

addressing the stroke market, a large, well-established and growing opportunity, and this

clear and deliberate strategic pivot underscores our vision of becoming a leading robotic

medical technology Company offering complete rehabilitation and mobility solutions for the

neurologically impaired from hospital to home.”

In the United States, stroke is the third leading cause of death and the leading cause of

serious, long-term disability. Stroke costs are estimated at $34 billion each year, including

services, medications and missed workdays. Approximately 795,000 people suffer a stroke

each year of which 650,000 people survive. The Company believes that over 400,000 of

those survivors are sufficiently impaired to benefit from interactive robotic therapy. There

are over 6.5 million stroke survivors in the U.S. alone, and in Europe, the numbers are

roughly 20-25% larger than in the U.S. and in China approximately 3 times larger, across

similar measures and with the same trending.

“The number of people worldwide affected by stroke has been growing rapidly, especially

in younger age groups and in low-to-middle-income countries. It is estimated that the

number of stroke patients are expected to double by 2030 and double again by 2050.

These numbers are absolutely staggering, but importantly, obviate the need for innovative

solutions for rehabilitation and recovery for stroke patients worldwide to address the

shortcomings of traditional treatment in addition to the socioeconomic impact that exists

globally. We plan to offer complete product solutions that treat the patients through the

continuum of care to ensure that every patient achieves their mobility goals,” added Mr.

Bloch.

Bionik provided an overview of its three U.S. Food and Drug Administration (FDA) cleared

commercial products and its four development stage programs expected to be advanced

towards commercialization.

Upper Extremity Commercial-Stage Rehabilitation Robots

InMotion ARM™ Interactive Therapy System

The InMotion ARM robot is designed to rehabilitate stroke patients with upper body

neurological limitations. The product is evidence based, intelligent, interactive technology

capable of continuously adapting to and challenging the patient's ability. This allows the

clinician to efficiently deliver personalized intensive sensorimotor therapy to neurologic

patients. The InMotion ARM is the most thoroughly researched robotic device for upper

extremity neurorehabilitation.

InMotion WRIST™ Interactive Therapy System

The InMotion WRIST robot is capable of lifting even a severely neurologically impaired

patient's hand against gravity, overcoming most forms of hypertonicity. The InMotion

WRIST robot accommodates the range of motion of a normal wrist in everyday tasks and

can be used by clinicians as a stand-alone treatment option or in addition to the InMotion

ARM to offer progressive modular robotic neurorehabilitation.

InMotion HAND™ Interactive Therapy System

The InMotion HAND robot is an add-on option to the InMotion ARM. The InMotion HAND

is capable of continuously adapting to the needs of each patient — delivering

customizable therapy. This module provides assist-as-needed™ grasp and release

training with flexible positioning. It may be used in neutral (vertical) or pronation mode for

patients with limited range due to developmental or tone impairments. The InMotion

HAND can be used to train grasp and release separately or in combination with the

reaching movements of the InMotion ARM.

Upper Extremity Development-Stage Rehabilitation Robots

InMotion ARM/WRIST/HAND Version 2 (AWH V2)

The InMotion AWH V2 is a current priority development project geared towards advancing

the existing InMotion products to improve the user experience and product design. No

additional regulatory or clinical data is required, and Bionik plans to launch this next

generation product line in the second quarter of 2017.

InMotion LIGHT

InMotion LIGHT is an upper extremity product that allows the patient to extend their

therapy for as long as needed while rehabilitating at home and is being developed on the

same design platform as the InMotion clinical products. The InMotion LIGHT is currently in

development and the Company expects to release it commercially in 2018.

“Stroke is a lifelong condition and nearly 70% of stroke patients requiring therapy are still

impaired enough to justify ongoing treatment beyond the initial phase of recovery and we

believe, would benefit significantly from home robotic therapy. This underserved patient

population, combined with the millions of people living with chronic neurological

impairment, is our justification for developing the InMotion LIGHT product and why we

believe the market opportunity is so large,” commented Hermano I. Krebs, Ph.D., M.S.,

the Company’s Chief Science Officer.

Lower Body Development-Stage Product Pipeline

ARKE Lower Body Exoskeleton

The ARKE lower body exoskeleton is designed to allow paraplegics and other wheelchair

bound individuals to walk and rehabilitate. ARKE has sensors throughout the device,

which sense body movement and trigger motion and is fully customizable to fit most

patients with different heights and weights. It includes a tablet interface which allows the

therapist to easily adjust all parameters of rehabilitation.

Validation testing is expected to continue through 2016. The Company then anticipates

the completion of clinical testing of ARKE 2.1 in the first quarter of 2017 and the

completion of clinical testing of ARKE 2.5 in the first quarter of 2018.

InMotion AnkleBot™

The InMotion AnkleBot is an exoskeletal robotic ankle system using the same design

principles in upper extremity rehabilitation. The InMotion AnkleBot is based on a design

developed at the Newman Laboratory for Biomechanics and Human Rehabilitation at MIT

and is currently available in multiple clinics for research in the U.S. The Company expects

to file for FDA clearance in the third quarter of 2017 with planned market introduction in

the first quarter of 2018.

In addition, Bionik has a new product candidate for gait assistance for rehabilitation based

on a design being developed by Dr. Krebs. The Company expects to further advance the

development of this product in 2017.

InMotion Products are Evidenced Based and Clinically Proven

There has been an extensive pool of research conducted that demonstrates the clinical

efficacy of the InMotion products in independent, randomized, controlled studies. Over

200 papers have been published and presented at prestigious scientific congresses and in

peer-reviewed journals. There have been more than 1,000 patients studied in clinical trials

with outcomes demonstrating clinical and economically significant results compared to

conventional therapy. The Company’s clinical studies meet the highest standard of

scientific rigor.

In addition to improved health outcomes, a randomized clinical trial demonstrated a 25%

reduction in total health care expenses over a 36-week period, as compared to a matching

intensity therapist delivered intervention. The 2010 and 2016 American Heart Association

(AHA) guidelines for stroke care, as well as the 2010 Department of Veterans Affairs poststroke

rehabilitation guidelines recommended robot assisted therapy for upper extremity

motor rehabilitation.

The Company previously announced its ongoing Robot Assisted Training for the Upper

Limb after Stroke (RATULS) study being led by Newcastle University under the auspices

of the National Institute for Health Research (NIHR) HTA Programme. This landmark study

is the largest ever conducted with robotics rehabilitation. This three-arm randomized

clinical trial enrolling 720 subjects across four study centers in the United Kingdom is

designed to determine whether robot assisted training improves upper limb function post

stroke using InMotion therapy products compared to enhanced upper limb therapy or

conventional therapy. The investigating team expects to complete the study in 2018 and

publish the results in 2019.

The Company believes the outcome of this study is expected to significantly impact

reimbursement for Bionik products as well as international market expansion.

Timothy A. McCarthy, Chief Commercialization Officer of Bionik commented, “The

commercial plan that we have put in place emphasizes Bionik’s competitive advantage,

which includes clinical evidence supporting improved outcomes and reduced overall cost

with robotic treatment when compared to conventional treatment. The Company’s

commercial plan is a potentially game-changing strategy to take control of the channel by

delivering clinically and economically proven robotic solutions throughout the continuum of

care for the neurologically impaired, which we believe will build enormous value to

shareholders.”

Growth Strategy Focused on Further Pipeline Expansion

Bionik’s growth strategy is designed to leverage its current product portfolio and internal

development programs. Its newly formed commercialization team is expected to build out

a robust sales and distribution channel. This includes leveraging sales models for the

product pipeline with revenue sharing, leasing and rental strategies.

Bionik’s management team expects to further leverage its in-depth research and

development relationships including those with professors at MIT to identify additional

synergistic robotic technologies. Over time, the Company expects to expand its product

pipeline through strategic partnering and acquisitions.

“Due to the huge market opportunity that exists, we plan to launch financing model options

for customers requiring flexibility, while we establish strategic partnerships with companies

who can support our efforts to build a comprehensive distribution network to access key

markets globally. Given our position in the market as the only evidence-based solution

and our robust product portfolio, we believe that with the right partners and people, we

have the right plan in place that will propel Bionik forward in a meaningful way, ultimately

enabling us to achieve our stated goal of becoming the leading robotic medical technology

company by offering complete rehabilitation solutions from hospital to home for the

neurologically impaired,” added Mr. McCarthy.

“We fully intend to build upon the groundwork and momentum we have created this year

and will continue to focus on operational excellence as we drive the development and

commercialization of our product portfolio forward. This is just the beginning for Bionik with

the many growth and value driving opportunities that exist for the Company in the near

and long term. I believe we have firmly positioned Bionik to become a leader in this

transformative shift from conventional to robotic treatment for neuro rehabilitation and most

importantly, significantly impact the lives of millions of individuals recovering from those

impairments, most notably stroke, and ultimately unlocking significant value for our

shareholders,” Mr. Bloch concluded.

About Bionik Laboratories

Bionik Laboratories (OTCQX:BNKL), is a global, pioneering robotics company focused on

providing rehabilitation and mobility solutions to individuals with neurological disorders.

The Company has a portfolio of products focused on upper and lower extremity

rehabilitation for stroke and paraplegic patients, including three products on the market

and four products in varying stages of development. The InMotion Systems - the InMotion

ARM™, InMotionWrist™, InMotion Hand™ and InMotion AnkleBot™, are designed to

provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to

maximize neuro-recovery. Bionik is also developing a lower-body exoskeleton, ARKE™,

designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate

through walking. ARKE is expected to be designed to continually adapt to a patient’s ability

and provide real time feedback to the physiotherapist.

For more information, please visit www.bioniklabs.com and connect with us on Twitter,

LinkedIn and Facebook.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may

constitute forward-looking statements. Forward-looking statements may include, without

limitation, statements regarding (i) the plans and objectives of management for future

operations, including plans or objectives relating to the design, development and

commercialization of human exoskeletons and other rehabilitation products, (ii) a

projection of income (including income/loss), earnings (including earnings/loss) per share,

capital expenditures, dividends, capital structure or other financial items, (iii) the

Company's future financial performance, (iv) the successful integration of IMT with Bionik,

(v) the successful integration of the Company’s new commercialization team and (vi) the

assumptions underlying or relating to any statement described in points (i), (ii), (iii), (iv) or

(v) above. Such forward-looking statements are not meant to predict or guarantee actual

results, performance, events or circumstances and may not be realized because they are

based upon the Company's current projections, plans, objectives, beliefs, expectations,

estimates and assumptions and are subject to a number of risks and uncertainties and

other influences, many of which the Company has no control over. Actual results and the

timing of certain events and circumstances may differ materially from those described by

the forward-looking statements as a result of these risks and uncertainties. Factors that

may influence or contribute to the inaccuracy of the forward-looking statements or cause

actual results to differ materially from expected or desired results may include, without

limitation, the Company's inability to obtain additional financing, the significant length of

time and resources associated with the development of our products and related

insufficient cash flows and resulting illiquidity, the Company's inability to expand the

Company's business, significant government regulation of medical devices and the

healthcare industry, lack of product diversification, volatility in the price of the Company's

raw materials, and the Company's failure to implement the Company's business plans or

strategies. These and other factors are identified and described in more detail in the

Company's filings with the SEC. The Company does not undertake to update these

forward-looking statements.

Bionik Laboratories, Inc. Investor and Media Contact:

Jenene Thomas

Jenene Thomas Communications, LLC

(908) 996-0239

jenene@jenenethomascommunications.com

Source: Bionik

More Less

Aug 8, 2016

Bionik Appoints New Chief Commerical Officer and Expands Commercial Team

August 8, 2016

Bionik Laboratories Appoints Timothy A. McCarthy as Chief Commercialization Officer and Expands Commercial Team

Experienced commercial leader in medical and healthcare technology

Top-producing and results-oriented leader with 20+ years of accomplishments in

developing commercial strategies, building world class global organizations and

growing multimillion-dollar revenues

Additional key appointments for expansion of sales representatives named to launch

commercial strategy

TORONTO and BOSTON, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Bionik Laboratories

Corp. (OTCQX:BNKL) (“Bionik” or the "Company"), a global pioneering robotics company

focused on providing rehabilitation solutions to individuals with neurological disorders,

announced today that it has appointed Timothy A. McCarthy to its Management Team as

Chief Commercialization Officer. Mr. McCarthy is a well-established and successful

commercial leader in medical and healthcare technology. The Company also announced

the addition of Steven L. Brown and Jon C. King to its newly formed global

commercialization team.

Peter Bloch, Chief Executive Officer and Chairman of the Board, stated, “We are delighted

to have Tim join the Bionik team. As a renowned expert in commercialization, and with the

experience he brings, we look forward to driving forward a strong commercial engine, the

number one priority for our growth strategy. This key strategic appointment is another

step for Bionik in positioning the Company as a leader in the robotics medical technology

and device space and propels us closer to bringing more effective rehabilitation solutions

to those with neurological disorders by utilizing innovative technologies and robotics.”

Timothy A. McCarthy joins the Bionik team having recently served as the Chief Executive

Officer of Medical Compression Systems, Inc., a medical device company specializing in

compression therapy to prevent DVT and improve wound healing for joint replacement

patients. He was recruited as the top executive at MCS to lead a commercial stabilization

and turnaround effort in order to prepare the company for an M&A process seeking a

strategic partner. Prior to that, Mr. McCarthy served as the President and CEO of iWALK,

Inc. (now known as BionX Medical Technologies), a venture backed medical robotics

company commercializing the Massachusetts Institute of Technology (“MIT”) invented

BiOM System, the world’s first and only actively powered lower limb bionic prosthesis to

normalize gait. While at iWALK, Inc. Mr. McCarthy was responsible for leading the final

product development and commercial sales strategy that led to the successful

establishment of a long-term market foothold for this new category of healthcare

technology products. In addition, Mr. McCarthy served at Össur Americas as Vice

President of Sales and Marketing, where he was promoted to the top commercial

executive and leader of a sales and marketing restructuring and growth effort, resulting in

above budget attainment each year and 4.5x revenue growth during his nine year tenure.

Mr. McCarthy also held sales leadership roles at the Chattanooga Group, Inc. (now known

as DJO Global). Over the course of his career Mr. McCarthy has proven to be instrumental

in the expansion of public, private and startup healthcare technology and medical device

companies.

“Robotic rehabilitation is an emerging market that represents a vast and growing

opportunity,” commented Mr. McCarthy. “The Bionik team and their range of robotic

rehabilitation systems show incredible promise in the robotic rehabilitation market and

ultimately beyond in the home setting. I am confident that the InMotion Systems and

ARKE have the potential to provide incredible opportunities for effective therapy for a

range of individuals suffering from neurological disorders. I look forward to leading the

Company’s commercial efforts and further advancing Bionik in this potentially fast growing

market to its next stage of growth.”

Mr. McCarthy graduated cum laude from Northeastern University with a Bachelor of

Science in Business Administration and received his Master of Business Administration

from the University of California in Los Angeles.

Bionik also appointed to its commercialization team two key sales executives, Steven L.

Brown and Jon C. King.

Steven L. Brown has over 35 years of significant contributions in key roles with industry

leaders in the field of Rehabilitation and Sports Medicine. Previous to joining the Bionik

team, Mr. Brown served as the National Business Development Manager at Bioness, Inc.

Over the course of his career, Mr. Brown has a diversified and proven management record

in sales, marketing, product management, strategic planning and commercialization.

Jon C. King is a domestic and international business development executive with over 25

years of experience in the field of Physical Medicine and Rehabilitation. Prior to joining the

Bionik team, Mr. King served as the Business Development Manager, Western Region

and Director of International Business Development at Bioness, Inc. Mr. King has a proven

history of increasing sales revenue and maintaining customer relationships on both a

national and international level.

“We are also pleased to welcome Steven Brown and Jon King to our commercialization

team. As we continue to advance Bionik and execute on our business strategy, we believe

these key appointments play an integral part in our ability to do so. We are excited to have

attracted these individuals and continue to focus our efforts on building a premier and

innovative robotics company achieving success globally,” concluded Mr. Bloch.

About Bionik Laboratories

Bionik Laboratories (OTCQX: BNKL), is a global, pioneering robotics company focused on

providing rehabilitation solutions to individuals with neurological disorders. The Company

has a portfolio of products focused on upper and lower extremity rehabilitation for stroke

and paraplegic patients, including three products on the market and three products in

varying stages of development. The InMotion Systems - the InMotion ARM™,

InMotionWrist™, InMotion Hand™ and InMotion Ankle™, are designed to provide

intelligent, patient-adaptive therapy in a manner that has been clinically verified to

maximize neuro-recovery. Bionik is also developing a lower-body exoskeleton, ARKE™,

designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate

through walking. ARKE is expected to be designed to continually adapt to a patient’s ability

and provide real time feedback to the physiotherapist through the use of Bionik’s

proprietary data collection and analytics cloud network through its partnership with IBM.

For more information, please visit www.bioniklabs.com and connect with us on Twitter,

LinkedIn and Facebook.

 Bionik Laboratories, Inc. Investor and Media Contact:

Jenene Thomas

Jenene Thomas Communications, LLC

(908) 996-0239

jenene@jenenethomascommunications.com

Source: Bionik Laboratories Corp.

More Less

Jun 14, 2016

RATULS Research Study Achieves 50% enrollment

RATULS Research Study of Robot-Assisted Training Achieves 50% Target Enrollment: Landmark Study Marks the Largest Trial Conducted to Date in Robotic Rehabilitation

 The Robot Assisted Training for the Upper Limb after Stroke (RATULS) study achieves 50% enrollment into a multicenter, randomized controlled research trial to evaluate the clinical and cost effectiveness of robot-assisted training in post-stroke care

 Study funded by the NIHR Health Technology Assessment (HTA) Programme conducted throughout the United Kingdom and employs the Bionik Laboratories InMotion Upper Extremity Robotic Gym

 Completion of enrollment of the 720 stroke patients expected before the end of 2018 with results to be published in 2019

Toronto, ON and Boston, MA – June 14, 2016 – Bionik Laboratories, Inc. (OTCQX: BNKL) ("Bionik" or the "Company"), a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, announced today that the study led by Newcastle University under the auspices of the National Institute for Health Research (NIHR) HTA Programme has achieved 50 percent enrollment for its multicenter, randomized controlled RATULS trial. The National Institute of Health Research (NIHR) is the research arm of the NHS in the UK which specifically commissioned this study having identified that robotic rehabilitation was necessary to further research. The investigating team expects to complete the study in 2018 and publish the results in 2019.

Newcastle University Professor of Stroke Care, Helen Rodgers, Principal Investigator of the study stated, "This landmark study is very important as it gives us the opportunity to evaluate the clinical and cost effectiveness of robotic rehabilitation in a clinical setting with a typical patient group. Importantly, the results of this study will inform the provision of robotic-assisted rehabilitation in clinical practice. It is critical that new health technologies are rigorously and independently evaluated as this will enable us to determine the effectiveness of robotic-assisted rehabilitation which has the potential to revolutionize rehabilitation treatment programs for stroke patients."

RATULS is a multicenter, randomized controlled trial to determine the clinical effectiveness of robot-assisted training upon upper limb function after stroke and is expected to enroll 720 participants. The stroke patients with reduced arm function who enroll in the study are randomly assigned to one of the three groups: robot-assisted training, enhanced upper limb therapy, or usual NHS rehabilitation. Robot-assisted training will be compared to an enhanced upper limb therapy program consisting of repeated practice of everyday activities using the arm and usual NHS rehabilitation.

The study consists of three therapy sessions per week lasting approximately one hour using the InMotion robotic gym system, involving training of the arm, wrist and hand. Effectiveness of robot-assisted training will be evaluated by comparing the upper limb function of patients in each 2

randomization group at 3 and 6 months. The primary outcome of the study is the evaluation of improvement for upper limb function at 3 months after randomization as measured by the Action Research Arm Test (ARAT). Secondary outcomes of the study include a number of improvements of upper limb function, as measured by evaluations including the Fugl-Meyer Test, Barthel ADL Index and the Stroke Impact Scale, as well as health economics, and qualitative patient and clinician satisfaction.

Hermano Krebs,Ph.D., M.S., Chief Science Officer of Bionik added, "We are thrilled to be a part of this landmark study, the largest of its kind to date. The RATULS research of robot-assisted therapy is important in the clinical development of the Bionik product pipeline as we aim to offer the best rehabilitation therapies for those affected by neurological disorders. For patients who suffer from a stroke, it is reported that 85% of those patients experience some loss in the ability to use the arm and hand. We believe that the InMotion systems offer people an effective opportunity for therapy to address the decrease in function they experience."

The study is being funded and conducted under the leadership of Newcastle University and is being funded by the NIHR Health Technology Assessment Programme. Enrollment for this study was initiated in April 2014. The investigating team plans to present the results at a scientific congress in 2019 and publish the data from this study in a scientific journal.

For more information about the study, please visit http://research.ncl.ac.uk/ratuls/forpatients/.

About InMotion Robot-Assisted Training

InMotion robot-assisted training consists of a series of visually-guided, visually-evoked computer games designed to track and challenge patients to complete movement exercises for the arm, wrist and hand. The InMotion systems are designed to gently assist patients with the movements that they are unable to complete alone and are used in an adaptive progressive fashion to challenge the patient to do his/her best. If patients are able to perform a movement then the robot reduces the level of assistance. Otherwise robot-assisted training enables weak or paralyzed patients to move their arm, wrist and hand to complete the task assisting the patients in their recovery.

About the National Institute for Health Research Health Technology Assessment Programme

This project is funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (project number 11/26/05). This article presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

1. The National Institute for Health Research Health Technology Assessment (NIHR HTA) Programme funds research about the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. It is the largest NIHR programme and publishes the results of its research in the Health Technology Assessment journal, with over 700 issues published to date. The journal’s 2014 Impact Factor (5.027) ranked 3

it two out of 85 publications in the Health Care Sciences and Services category. All issues are available for download, free of charge, from the website. The HTA Programme is funded by the NIHR, with contributions from the CSO in Scotland, NISCHR in Wales, and the HSC R&D Division, Public Health Agency in Northern Ireland. www.nets.nihr.ac.uk/programmes/hta

2. The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website (www.nihr.ac.uk).

About Bionik Laboratories

Bionik Laboratories (OTCQX: BNKL), is a global, pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders. Through the acquisition of Interactive Motion Technologies, Bionik has added a portfolio of products focused on upper and lower extremity rehabilitation of stroke patients. The Company now has three products on the market and two products in varying stages of development that it is currently pursuing. The InMotion Systems - the InMotion ARM™ InMotion WRIST™ InMotion ARM/Hand™and InMotion ANKLE™, are designed to provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery. Bionik is also developing a lower-body exoskeleton, ARKE™ designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking. Each of Bionik’s products are or are expected to be designed to continually adapt to a patient’s ability and provide real time feedback to the physiotherapist through the use of Bionik’s proprietary data collection and analytics cloud network through its partnership with IBM.

For more information, please visit www.bioniklabs.com and connect with us on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the successful integration of IMT with Bionik and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not 4

be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.

Bionik Laboratories, Inc. Investor and Media Contact: Jenene Thomas Jenene Thomas Communications, LLC (908) 996-0239

jenene@jenenethomascommunications.com

SOURCE: Bionik Laboratories Corp.

###

More Less

About us

Company details

BIONIK is the global pioneer and leader in providing rehabilitation solutions to individuals with neurological disorders. Formerly known as Interactive Motion Technologies, Bionik is now able to offer a full portfolio of upper and lower extremity robotic systems designed for neurorehabilitation. Conceived and researched at the Massachusetts Institute of Technology’s (MIT) Newman Laboratory for Biomechanics and Human Rehabilitation, InMotion Robotic Neurorecovery Systems are the most thoroughly researched upper extremity neurorehabilitation technology in the world. InMotion Robotic Neuro-Recovery Systems provide intelligent, customized therapy in the intense manner required to achieve development of new neural pathways.  

The InMotion ARM/HAND and InMotion WRIST Robotic Neurorecovery Systems feature evidence-based, interactive technology that senses patient movements and limitations, providing assistance-as-needed in real-time. The technology not only prompts participation and provides consistency, it also encourages appropriate movement while discouraging movement that is inappropriate. By automatically and continuously adapting to and challenging each patient’s ability, the intelligent algorithms behind InMotion systems enable clinicians to automatically deliver personalized intensive shoulder, elbow, hand and wrist sensorimotor therapy to patients with mild to severe impairments. More important, the unique therapy these systems offer promotes development of new neural pathways resulting in marked and meaningful improvement when compared with usual care and treatment.

Scores of independent and controlled studies conducted at world-leading research institutions over twenty years, involving more than 1200 clinical subjects, show clear improvement in both adults and children with moderate to severe impairment, even years post-stroke. Assessments using the most widely accepted tests of functional ability—FIM, Fugl-Meyer and Wolf Motor Function—support the findings. Subjects in acute, sub-acute and chronic treatment settings took part in these clinical studies, validating efficacy of InMotion Systems across a broad range of settings.  

The level, consistency and sustainability of improvement is unparalleled—robotic therapy delivered with InMotion Robotic Neurorecovery Systems augments the body’s remarkable capability to learn, reacquire and improve motor skills using the brain’s inherent neuroplasticity. No other products on the market come close to demonstrating results like this. With these systems, BIONIK is redefining recovery for patients suffering from neurological impairments, including stroke, cerebral palsy, and spinal cord Injury. 

We are also developing a lower-body exoskeleton designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking

More Less

Company data

Sales volume

1-9 Mio US $

Export content

max. 75%

Number of employees

20-49

Area of business
  • Electromedical equipment / Medical Technology
  • Physiotherapy / Orthopaedic Technology